Ancient founder mutation is responsible for Imerslund-Gräsbeck Syndrome among diverse ethnicities by Beech, Cameron M et al.
RESEARCH Open Access
Ancient founder mutation is responsible for
Imerslund-Gräsbeck Syndrome among diverse
ethnicities
Cameron M Beech
1†, Sandya Liyanarachchi
1†, Nidhi P Shah
1, Amy C Sturm
1,2, May F Sadiq
3, Albert de la Chapelle
1
and Stephan M Tanner
1*
Abstract
Background: Imerslund-Gräsbeck syndrome (IGS) was described just over 50 years ago by Olga Imerslund and
Ralph Gräsbeck and colleagues. IGS is caused by specific malabsorption of cobalamin (Cbl) due to bi-allelic
mutations in either the cubilin gene (CUBN) or the human amnionless homolog (AMN). Mutations in the two genes
are commonly seen in founder populations or in societies with a high degree of consanguineous marriages. One
particular mutation in AMN, c.208-2A>G, causing an out-of-frame loss of exon 4 in the mRNA, is responsible for
some 15% of IGS cases globally. We present evidence that this founder mutation causes a substantial percentage
of cases among diverse ethnicities and that the mutation is as old as human civilization.
Methods: Partial genotyping indicated a founder event but its presence in diverse peoples of Arabic, Turkish,
Jewish, and Hispanic ancestry suggested that the mutation might be recurrent. We therefore studied the flanking
sequence spanning 3.5 Mb to elucidate the origin of the haplotype and estimate the age of the mutation using a
Bayesian inference method based on observed linkage disequilibrium.
Results: The mutation’s distribution, the size of the shared haplotype, and estimates of growth rate and carrier
frequency indicated that the mutation was a single prehistoric event. Dating back to the ancient Middle East
around 11,600 BC, the mutation predates the advent of writing, farming, and the monotheistic religions of the
region.
Conclusions: This mutation causes over 50% of the IGS cases among Arabic, Turkish, and Sephardic Jewish
families, making it a primary target for genetic screening among diverse IGS cases originating from the Middle East.
Thus, rare founder mutations may cause a substantial number of cases, even among diverse ethnicities not usually
thought to be related.
Keywords: Imerslund-Gräsbeck syndrome, juvenile cobalamin deficiency, founder mutation, age estimation, muta-
tion screening, anemia, ethnicity
Background
Imerslund-Gräsbeck syndrome (IGS, megaloblastic ane-
mia 1; OMIM261100) is a recessively inherited child-
hood disorder[1]. IGS is prevalent in societies where
consanguinity is common or in communities that under-
went a population bottleneck [2]. The disease is
manifested by an increased propensity for infections,
fatigue, attention deficit, paralysis, and ultimately mega-
loblastic anemia that can be fatal if left untreated. The
primary diagnostic criteria are reduced vitamin B12
levels in the serum, elevated homocysteine and methyl-
malonic acid levels in the blood and urine, and often
mild proteinuria [3]. The disorder, which is caused by
selective malabsorption of cobalamin (Cbl; vitamin B12)
in the intestine, occurs due to bi-allelic mutations in
either the cubilin (CUBN, OMIM602997 [4]) or the
amnionless gene (AMN, OMIM605799 [2,5]. The
* Correspondence: stephan.tanner@osumc.edu
† Contributed equally
1Comprehensive Cancer Center, The Ohio State University, Columbus, OH
43210, USA
Full list of author information is available at the end of the article
Beech et al. Orphanet Journal of Rare Diseases 2011, 6:74
http://www.ojrd.com/content/6/1/74
© 2011 Beech et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.proteins encoded by CUBN and AMN form a cellular
receptor named cubam found on the enterocytes in the
ileum, renal tubular cells, and cells of the yolk sac. In
the intestine, cubam facilitates the absorption of Cbl
and other nutrients from the food, and in the kidneys,
cubam is responsible for protein reabsorption [6].
Cubam is further required for patterning of the rodent
embryo [7] but its role in human development is pre-
sently unclear [8]. Interestingly, mutations in the GIF
gene coding for gastric intrinsic factor have been impli-
cated in Intrinsic Factor Deficiency (IFD; OMIM261000
[9-11]), a disease with similar symptoms except for pro-
teinuria, which is not seen in IFD. Both IGS and IFD
are treatable with life-long parenteral Cbl supplementa-
tion, which alleviates the symptoms except the treat-
ment-resistant proteinuria in IGS [3].
Diagnosing IGS is a time-consuming and often
inconclusive procedure mainly based on excluding
other causes of Cbl deficiency, of which there are
many [3]. Genetic diagnostics is not widely available
and is far from straightforward because of the genetic
heterogeneity. We have screened over 150 patients or
sibships with recessive hereditary Cbl malabsorption in
the past 10 years ([2,5,10,11] and SMT unpublished
data). About 80% were mutated in either AMN or
CUBN (causing IGS) or GIF (causing IFD), while the
ABCC1 gene was excluded [12]. Early on, we docu-
mented four IGS patients from three families (two
Turkish and one Sephardic Jewish) with the homozy-
gous splice site mutation c.208-2A>G in intron 3 of
AMN [2]. This mutation causes exon 4 (88 bp) to be
skipped in the messenger RNA and results in a frame-
s h i f tt h a tl e a d st oat r u n c a t e dAMN protein [5]. Lim-
ited genotyping suggested that these four patients
shared a similar haplotype flanking the mutation [2].
S i n c et h e nw eh a v ei d e n t i f i e d an additional 16 patients
from 13 unrelated families, for a total of 20 patients
from 16 sibships, all homozygous for the AMN c.208-
2A>G mutation (Additional file 1). Most families were
of Sephardic Jewish (4) or Turkish descent (7) but also
included Arabic families from Jordan (3). One case
from the USA had Hispanic roots but based on the
name was judged to be of Jewish ancestry and one
case was from Spain without detailed ethnic informa-
tion. The occurrence of this particular mutation in
patients originating mainly from the Eastern Mediter-
ranean supported that c.208-2A>G might be a founder
mutation. However, its incidence among these different
ethnicities and across a large geographic region chal-
lenged that notion. The alternative explanation was
that c.208-2A>G was a recurrent molecular defect,
arising repeatedly de novo. Given that this mutation is
the most frequent cause of IGS outside Scandinavia,
clarifying its origin was of clinical importance.
Methods
Patient samples and controls
A total of 20 patients with IGS (9 female, 11 male, ages
2-19 years when diagnosed), 24 parents, 8 unaffected
siblings, and 4 grandparents from 16 IGS families were
included in this study (Additional file 1 and Figure 1).
Patients with IGS were diagnosed based on established
criteria [1,13], while the parents were healthy. All the
families were allegedly unrelated. Thirty-six anonymous
Jordanian controls (Arabs, ages > 18 years) were
obtained from the Department of Biological Sciences,
Yarmouk University in Irbid, Jordan.
Mutation screening and genotyping
Genomic DNA was extracted from white blood cells
using standard phenol-chloroform-ethanol precipitation
after written informed consent according to institutional
review board guidelines of the Ohio State University
and the Declaration of Helsinki. Molecular diagnosis
involved screening the AMN and CUBN genes for sus-
pected IGS. Individual exons of AMN or CUBN were
amplified by PCR and analyzed as previously described
[2,5]. After identifying the AMN c.208-2A>G mutation
in exon 4, DNA samples from cases and family mem-
bers were genotyped.
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Figure 1 Pedigrees of 16 sibships with Imerslund-Gräsbeck
mutation AMN c.208-2A>G. Full symbols denote patients with IGS.
Only individuals from whom DNA was available for mutation
analysis and genotyping are shown. The individual from whom a
sample was used for the estimation of the age of the mutation is
marked by an asterisk.
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Page 2 of 6Flanking markers from 2.3 Mb centromeric to 1.2 Mb
telomeric of the AMN locus were genotyped, including
18 microsatellites (AMNM11, AMNM12, D14S1051,
AMNM13, D14S577, G35981, AMNM3, AMNM4,
D14S272, AMNM5, AMNM6, AMNM7, AMNM1,
D14S293, AMNM14, AMNM8, AMNM15, AMNM10)a n d
11 single nucleotide polymorphisms (rs1211497,
rs59793431, rs57687948, rs2295828, rs2295829,
rs1190225, rs1190228, rs1190229, c.1169+42S, rs1190233,
rs35285749; Figure 2). The microsatellites labeled
AMNMn and G35981 were simple-sequence tandem-
repeats identified by repeat masker. The microsatellites
w e r eg e n o t y p e du s i n gF A M - l a b e l e dp r i m e r sa n dt h e
Genotyper program, while the SNPs were typed by
SNaPshot (Applied Biosystems, Foster City, CA).
Haplotype construction
Obtained genotype data were used to construct haplo-
types using the linkage program Merlin [14] and the
PHASE 2.0 program [15] according to their manuals.
Age estimation
Mutation age estimate was carried out with the DMLE
+2.3 software program [16] using the 29 loci genotyped.
In order to do so, the proportion of disease haplotypes
sampled and the growth rate were estimated. For the
Sephardim, we used an estimate of ~2 million for its
population, while for the Muslim source population we
added up Turkey (~76.5 million) and Jordan (~6.5 mil-
lion), for a total of 83 million [17]. The proportion of
disease chromosomes sampled depended on an estimate
of the mutation frequency, which was unknown. Thus,
the incidence rate of IGS was estimated at 1 case per
10,000, 1:100,000, 1:500,000 and 1:1,000,000 people for a
calculated carrier frequency of the mutation of 1 in 100,
1 in 316, 1 in 707, and 1 in 1,000 individuals, respec-
tively. Turkey has a current population growth rate of
1.24% and Jordan’s is 0.98% per year [17]. Before 1 AD
the annual population growth rate was potentially less
than ~1% [18,19]. Thus, for the growth rate a range of
values (1-3%) was used for the calculations in part based
on the growth rates by Zelinger and colleagues [20].
Results & Discussion
Mutation haplotype
The haplotyping results indicated that two almost iden-
tical haplotypes carried the mutation. One was found in
the 5 “Jewish” families (4 Sephardic and one Hispanic)
and the other in the 10 “Muslim” (Turkish and Jorda-
nian) families. The sole Spanish case (patient family 30;
Figure 1) carried a “Jewish” and a “Muslim” haplotype.
The Jewish haplotype differed from the Muslim haplo-
type - with a few exceptions - at marker D14S1051
(genotype 182/180), two SNPs upstream of exon 1
(rs2295828, rs2295829), and marker AMNM1 (192/190);
i.e. the Jewish haplotype is 182-C-C-192 and the Muslim
haplotype is 180-T-G-190 (Additional file 1 and Figure
2). At first, this suggested that we observed separate
Jewish and Muslim mutational events, in particular
because the two SNPs are only 5.8 kb upstream from
the mutation c.208-2A>G. However, the two haplotypes
shared all alleles up to marker D14S272,w h i c hi s1 1 7
kb centromeric to the mutation, and likewise 60 kb telo-
meric to the mutation marker D14S293 delimited a
common conserved haplotype. Moreover, alleles from
AMNM13 to AMNM14 were by and large identical
on both haplotypes, indicating that a mutation proto-
haplotype of at least 950 kb was shared (Additional file
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Figure 2 Map of the AMN gene locus in chromosome band 14q32. Eighteen microsatellite markers flanking AMN from 2.3 Mb centromeric
to 1.2 Mb telomeric are shown above the upper line. Eleven single nucleotide polymorphisms between AMNM6 and AMNM7 and centering on
the AMN gene locus are shown in the enlarged region below. The AMN gene is depicted as a black rectangle and the mutation is underlined.
All 29 marker loci were used for genotyping and age calculations (see text). Physical distances are not drawn to scale.
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Page 3 of 61 and Figure 2). This fact supported the concept that we
observed a single mutational event and that the micro-
satellite markers D14S1051, AMNM1, and the two SNPs
(rs2295828, rs2295829) were mutated or recombined
later.
Age of the mutation
We first combined the two ethnic groups for age esti-
m a t i o n .O ft h e2 0p a t i e n t s ,1 6( 5J e w i s h ,1 0M u s l i m ,
and one compound Spanish case) were unrelated and
selected for age calculation, resulting in 32 disease chro-
mosomes. The sum of the populations was 85 million.
We also concluded that the frequency of IGS is likely
greater than 1 in 1 million; at least among the Sephardic
Jews with 5 confirmed patients among ~2 million peo-
ple. The 10 cases among 83 million Turks and Jorda-
nians are probably underestimated because of lack of
local genetic testing. We noted that four of the ten
Muslim cases were diagnosed among expatriates in Eur-
ope. Thus, we estimate the IGS incidence for both
groups caused by this mutation to be around 1 in
500,000 people for a carrier frequency of 1:707 but we
calculated the age for various incidences (Additional file
2). After applying the different growth rates, the age was
estimated to be between 8,050 years (95% confidence
interval [CI] 6,450-11,200 years) and 19,225 years (95%
CI: 14,300-28,600 years) for an average of ~13,600 years
(~11,600 BC).
If the mutation originated around 11,600 BC it could
explain why it is today seen in the peoples of Turkey
and Jordan but not necessarily why it is only present
in Jews of Sephardic roots. We would expect the muta-
tion to be present in various Jewish groups because of
their common roots [21,22]. However, to date we have
only studied three other unrelated Jewish IGS patients,
who were all Ashkenazi. Two of these carried a homo-
zygous CUBN mutation, c.2614_2615delGA; p.D872fs
(SMT unpublished data), and one was compound het-
erozygous for AMN c.43+1G>T; splice site &
c.701G>T; C234F [23]. Since Ashkenazim are generally
aware of modern genetic research, the absence of the
AMN mutation c.208-2A>G among them suggested
that it was never present in their founder population.
The lack of c.208-2A>G in other Jewish groups of the
Diaspora could have a similar explanation. Conse-
quently, the mutation’s exclusive presence among
Sephardic Jews suggested that the mutation had
entered that Jewish group from a non-Jewish back-
ground rather than the other way. When the age cal-
culations were repeated by separating the cohort into
Jews (2 million and 10 chromosomes) and Muslims (83
million and 20 chromosomes) - the mixed case was
removed - we estimated the age to be between 4,275
years (95% CI: 2,875-7,475 years) and 10,975 years
(95% CI: 5,525-19,975 years) for the Jewish haplotype
and between 7,225 years (95% CI: 5,600-9,875 years)
and 19,000 years (95% CI: 13,625-26,650 years) for the
Muslim haplotype (Additional file 2). Thus indeed, the
Muslim haplotype appeared to be older than the Jew-
ish haplotype. However, the Jewish population was
much smaller, thus the proportion of disease chromo-
somes sampled became greater. This caused the Jewish
haplotype to appear younger than it probably is (Addi-
tional file 2). The size of the conserved haplotype
(when ignoring D14S1051, AMNM1,a n dt h et w oS N P s
rs2295828 and rs2295829) was about the same in both
groups (~1 Mb), suggesting a similar age and origin.
The alternative explanation of two identical mutational
events in Jews and Muslims would have to assume that
the mutation occurred twice around the same time,
judged from the haplotype size. Moreover, it would
have to have affected two almost identical haplotypes.
When studying the frequency of the proto-haplotype
among 36 Jordanian controls, we detected it only once
among 72 chromosomes (Additional file 1). Thus, the
probability of two identical mutations occurring
around the same time on the same rather rare haplo-
type is low. In addition, this mutational event has
apparently never happened again, thus the evidence
was not supporting a mutational hotspot mechanism.
In fact, the consistent differences between the Muslim
and the Sephardic haplotypes at D14S1051, AMNM1,
and the two SNPs rs2295828 and rs2295829 point to
single split and no subsequent convergence until today.
The “compound heterozygous” Spanish patient (family
30) indeed may be the product of Sephardic and later
Muslim migration to Spain [24]. The Hispanic case
from the USA might also be traced back to the Iberian
Peninsula and the expulsion of Jews from there in
1492 AD, which also brought them to the New World.
Finally, two more IGS cases with this mutation were
described in the literature, one from Tunisia, albeit
without further ethnic details [25], and another from
Austria with Turkish ancestry [26].
The oldest known founder mutation to date appears
to be the deltaF508 in the cystic fibrosis gene CFTR that
was estimated to be 11,000-52,000 years old depending
on genetic (microsatellite mutation rate and selection)
and demographic (growth rate and population size)
parameters [27,28] but its population origin remains
enigmatic [29]. While certain CFTR mutations are
hypothesized to convey a selective advantage [30], to
our knowledge there is no known benefit for healthy
heterozygous carriers of IGS mutations, thus a heterosis
effect is unlikely. While the exact frequency of IGS car-
riers remains unknown, the incidence of IGS is probably
higher than one would expect from the carrier fre-
quency because of a high degree of consanguinity.
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We have used a series of assumptions to estimate the age
range of a founder mutation in AMN that causes IGS. Jud-
ging the data conservatively, we believe that the region of
origin for the mutation to be in Northern Mesopotamia
(today’s Eastern Turkey and Northern Iraq) some 13,600
years ago, placing it before the beginning of the Neolithic
period (ca. 9,500 BC). Its exclusive presence in Sephardic
Jews today could be explained by a common ancestor in
an early Semitic population whose descendants contribu-
ted to that Jewish tribe as well as the Turkish and Arabic
populations we recognize today. The natural history of
this mutation is in agreement with recent studies that sup-
port a common but complex ancestry between Jews and
non-Jews in the Middle East [21,22].
Although AMN c.208-2A>G is apparently younger
than CFTR deltaF508, it appears to be one of the oldest
human disease mutations known to date and clearly
occurred first in the Middle East. It causes some 15% of
IGS cases worldwide and more than 50% among Turks,
Jordanians, and Sephardim combined (SMT unpublished
data). Given that the genetic analysis for newly diag-
nosed IGS cases is complex, AMN c.208-2A>G should
be considered first when dealing with patients originat-
ing from Turkey, Jordan, Spain, Tunisia, or with an eth-
nic Sephardic background.
Additional material
Additional file 1: Genotypes of 16 sibships with AMN mutation
c.208-2A>G and haplotype information of 36 Jordanian controls.
Detailed genotype and haplotype data of 29 markers flanking the AMN
gene. The mutation haplotypes for Jewish and Muslim patients are
identified by color.
Additional file 2: Age estimation with DMLE+2.3 for AMN mutation
c.208-2A>G. Age estimation calculations based on various growth rates
and carrier frequencies as indicated in the text.
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